Totaligent, Inc. 8-K

What Happened

• On April 10, 2026 Totaligent, Inc. entered a Definitive Agreement with Ivan Klarich to effect a strategic acqui‑hire of Aetherium’s team and related intangible assets into a new wholly‑owned subsidiary, Aetherium Medical LLC. The agreement supersedes a prior LOI and names Klarich President immediately upon execution and a member of Totaligent’s Board following closing.
• The deal calls for milestone‑based equity (Series D Preferred convertible into 1,000 shares of Common Stock, or Common Stock at the company’s election), including an initial 10% fully‑diluted equity grant at closing and additional issuances tied to joint ventures, partnerships, revenue targets and a potential uplist/qualified IPO. Closing is scheduled 30 days after the Effective Date, subject to customary conditions and certain officer/consultant salary reductions.

Key Details

• Agreement date: April 10, 2026; filing date of this Form 8‑K: April 15, 2026.
• New subsidiary: Aetherium Medical LLC (wholly owned Delaware LLC) will receive the Aetherium Assets (primarily trade secrets, know‑how, business relationships; no registered patents/trademarks or third‑party liabilities).
• Leadership: Ivan Klarich appointed President immediately and will join an expanded three‑member Board after closing; an employment agreement will be executed on industry‑standard terms.
• Consideration & timing: Initial 10% fully‑diluted equity issuance at closing; Series D convertible treatment and additional milestone/true‑up grants tied to specific performance events; closing targeted ~30 days after the Effective Date.

Why It Matters

• For investors, the transaction brings new management and medtech assets to Totaligent without taking on known third‑party liabilities, which could accelerate product or commercial initiatives.
• The equity grants (including an immediate 10% fully‑diluted issuance plus milestone awards) will dilute existing shareholders and tie substantial compensation to performance and an uplist/IPO outcome.
• The agreement contemplates but does not require a separate joint venture with GloMed, so potential strategic expansion is possible but not guaranteed. Closing remains subject to customary conditions (employment agreements and other approvals).